About the Company
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PTLA News
Madrigal Pharma CFO Alex Howarth Quits, Mardi Dier Named Replacement
Dier has more than 20 years of experience in executive financial leadership roles and was the finance chief in companies like Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin ...
Global Cerebral Vein Thrombosis Treatment Market to Reach US$ 611 Million by 2033
Cerebral Vein Thrombosis Treatment Market is projected to 12.3% CAGR, is expected to reach an estimated value of US$ 611 ...
CRVS Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers ...
NRBO NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241 ...
Global Blood Preparation Market Size To Exceed USD 82.75 Billion By 2033 | CAGR Of 6.01%
(MENAFN- GlobeNewsWire - Nasdaq) The Global Blood Preparation Market Size was Valued at USD 46.15 Billion in 2023 and the Worldwide Blood Preparation Market Size is Expected to Reach USD 82.75 ...
Madrigal Pharmaceuticals, Inc. (MDGL)
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday ...
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Fidelity Management & Research Co. 3Q 13F: Largest Eliminations
SUSQUEHANNA BANCSHARES INC CO SUSQ (649,081) PORTOLA PHARMACEUTICALS INC C PTLA (644,600) CALUMET SPECIALTY PRODUCTS UN CLMT (626,112) DUCOMMUN INC (DEL) COM DCO (617,417) SEABRIDGE GOLD INC COM ...
Catalyst Pharmaceuticals, Inc. (CPRX)
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ETCORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or ...
Vanda Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead ...
Loading the latest forecasts...